Literature DB >> 29097157

Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model.

Mariane Dos Santos1, Gaia Favero2, Francesca Bonomini3, Alessandra Stacchiotti3, Luigi Fabrizio Rodella3, Francisco Veríssimo Veronese1, Rita Rezzani4.   

Abstract

AIMS: Since lupus nephritis (LN) etiopathogenesis is not fully understood, herein we investigated the morphological basis of LN in mice induced with pristane. MAIN
METHODS: To evaluate the melatonin effects in these animals, we studied the renal cytoarchitecture by means of morphological analyses, immunofluorescence expression of specific markers related to fibrosis, oxidative stress, inflammation and apoptosis. KEY
FINDINGS: We observed that pristane-LN mice have serious alterations in the kidney cytoarchitecture, i.e. tubular degeneration, glomerular hypercellularity, matrix mesangial expansion and interstitial inflammation. The pristane-induced LN mice treated with melatonin exhibited a well preserved cytoarchitecture. SIGNIFICANCE: Our results document that LN etiopathogenesis is related to both tubular damage and glomerular lesions. We suggest that it is essential to take in consideration both these lesions for LN diagnosis and classification. Clearly, we show that the use of melatonin may be a possible therapeutic strategy for improvement the renal injury in this disorder.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Fibrosis; Lupus; Mesangial cells; Oxidative stress; Proximal tubule

Mesh:

Substances:

Year:  2017        PMID: 29097157     DOI: 10.1016/j.lfs.2017.10.038

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 2.  Dietary Melatonin Supplementation Could Be a Promising Preventing/Therapeutic Approach for a Variety of Liver Diseases.

Authors:  Francesca Bonomini; Elisa Borsani; Gaia Favero; Luigi F Rodella; Rita Rezzani
Journal:  Nutrients       Date:  2018-08-21       Impact factor: 5.717

3.  A carnosine analog with therapeutic potentials in the treatment of disorders related to oxidative stress.

Authors:  Rita Rezzani; Gaia Favero; Matteo Ferroni; Claudio Lonati; Mohammed H Moghadasian
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

4.  Combined melatonin and poricoic acid A inhibits renal fibrosis through modulating the interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum.

Authors:  Dan-Qian Chen; Gang Cao; Hui Zhao; Lin Chen; Tian Yang; Ming Wang; Nosratola D Vaziri; Yan Guo; Ying-Yong Zhao
Journal:  Ther Adv Chronic Dis       Date:  2019-08-14       Impact factor: 5.091

5.  Melatonin exerts immunoregulatory effects by balancing peripheral effector and regulatory T helper cells in myasthenia gravis.

Authors:  Ting Chang; Chunxiao Niu; Chao Sun; Ying Ma; Rongjing Guo; Zhe Ruan; Yanwu Gao; Xiaodan Lu; Huanhuan Li; Ye Lin; Jiaji Lin; Zhuyi Li
Journal:  Aging (Albany NY)       Date:  2020-11-02       Impact factor: 5.682

6.  Melatonin Protects Human Renal Proximal Tubule Epithelial Cells Against High Glucose-Mediated Fibrosis via the Cellular Prion Protein-TGF-β-Smad Signaling Axis.

Authors:  Yong-Seok Han; Yeo Min Yoon; Gyeongyun Go; Jun Hee Lee; Sang Hun Lee
Journal:  Int J Med Sci       Date:  2020-05-18       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.